PO-322 has potent immunosuppressive activity in vitro and in vivo by selectively inhibiting SGK1 activity.
Immunosuppressive drugs have shown great promise in treating the autoimmune diseases in recent years. A series of novel oxazole derivatives were screened for their immunosuppressive activity. PO-322 [1H-indole-2,3-dione 3-(1,3-benzoxazol-2-ylhydrazone)] was identified as the most effective of these compounds. The purpose of the current study was to investigate the potential mechanism of PO-322 in inhibiting T cell proliferation in vitro, as well as its effects on the delayed-type hypersensitivity response and imiquimod-induced dermatitis in vivo. T cell proliferation and apoptosis were analysed with flow cytometry. Cell viability was assessed with a CCK-8 assay. Protein kinase activity was assessed by SelectScreen Kinase Profiling Services. The phosphorylation of signal-regulated molecules was measured by western blot. Cytokine levels were determined by ELISA. The effect of PO-322 on delayed-type hypersensitivity and imiquimod-induced dermatitis was evaluated in a mouse model. PO-322 inhibited human T cell proliferation with anti-CD3/anti-CD28 mAbs or alloantigen without significant cytotoxicity. Importantly, PO-322 was a selective SGK1 inhibitor and decreased NDRG1 phosphorylation but not p70S6K, STAT5, AKT or ERK 1/2 phosphorylation. Furthermore, PO-322 inhibited IFN-γ, IL-6 and IL-17 expression but not IL-10 expression. Finally, the administration of PO-322 was safe and effective for ameliorating the delayed-type hypersensitivity response and imiquimod-induced dermatitis. Taken together, PO-322 exerts immunosuppressive activity in vitro and in vivo by selectively inhibiting SGK1 activity. PO-322 represents a potential lead compound for the design and development of new drugs for the treatment of the autoimmune diseases.